Till now, long-standing or chronic diseases such as high blood pressure, diabetes and antibiotics were in the forefront of sales. But now the sales of the gynecology pill, drugs used to treat infertility and menstrual problems in women are overtaking it. Experts say that the increase of gynecological diseases is a serious topic. Now it is seen that the demand for the molecule Dydrogesterone has also increased significantly.
Due to this increasing infertility
According to doctors, due to negligence in office work, tension and food, cases of infertility are increasing now. Now these cases are being seen more in women. This is a matter of concern. If attention is not given, then these diseases are going to increase in the coming time.
The boom came after the year 2020
In the year 2020, Mankind first launched this drug as a generic. After this many other companies including Emcure, Alkem, Torrent and Eris also started making it.
Till three years ago, the sale of this drug was the highest.
According to the news published in TOI, until three years ago, Abbott’s brand Duphaston was the only drug prescribed for the treatment of female infertility, period pain. Due to this, its sales were close to Rs 350 crore annually. This medicine was made in the Netherlands. Now this market has expanded due to the manufacture of this medicine by other companies as well. In FY22, 50% of branded generic Dydrogesterone sales excluding Duphaston have reached Rs 250 crore in this two-year time frame.
Improved drug availability
According to a report in The Times of India, Krishnakumar V, COO and ED, Eris Life Sciences, said that the reach and availability of this product has improved significantly with several companies launching dydrogesterone. Now people are able to buy it easily. Its sales have increased. In FY22, the market for natural progesterone was around Rs 700 crore. Dydrogesterone volumes have increased by 48% in FY22.
Source: navbharattimes.indiatimes.com
: Language Inputs
This post is sourced from newspapers, magazines and third-party websites. For more information please check NewsDay Express Disclaimer.